No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus
Andrea Snow‐Lampart, Brandi Chappell, Maria Curtis, Yuao Zhu, Florence Myrick, James Schawalder, Kathryn Kitrinos, Evguenia S. Svarovskaia, Michael D. Miller, Jeff Sorbel, Jenny Heathcote, Patrick Marcellin, Katyna Borroto‐Esoda – 18 November 2010 – Tenofovir disoproxil fumarate (TDF) is a nucleotide analogue with potent activity against human immunodeficiency virus type 1 and hepatitis B virus (HBV). To date, no reports of HBV clinical resistance to TDF have been confirmed.